Lenacapavir
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 391 publications
FDAs new approval: yeztugo (lenacapavir): A longer lasting avenue against HIV.
Journal: JPMA. The Journal of the Pakistan Medical Association
Published: September 07, 2026
Lenacapavir binding to immature Gag induces giant virions and causes protease-dependent inhibition of viral release.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: September 03, 2026
Lenacapavir allosterically remodels the HIV-1 capsid.
Journal: Science advances
Published: September 02, 2026
Evaluating the combination of bictegravir and lenacapavir as a single tablet option for HIV.
Journal: Expert opinion on pharmacotherapy
Published: September 01, 2026
Progress toward longer-acting antiretroviral regimens for adult HIV treatment.
Journal: Expert review of clinical pharmacology
Published: August 26, 2026
Lenacapavir for HIV Prevention in Africa: Opportunities, Barriers, and Policy Priorities.
Journal: Journal of the International Association of Providers of AIDS Care
Published: August 25, 2026
Once-weekly oral islatravir plus lenacapavir: clinical considerations for individualized use.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: August 24, 2026
Capsid stabilization reprograms the nuclear fate of the HIV genome.
Journal: Science advances
Published: August 07, 2026
Lenacapavir: a first-in-class HIV-1 capsid inhibitor: Erratum.
Journal: Current opinion in HIV and AIDS
Published: August 06, 2026
Provider Perspectives on the Delivery of Long-Acting PrEP for HIV Prevention to Men Who Have Sex with Men and Who Use Methamphetamine.
Journal: AIDS patient care and STDs
Published: August 05, 2026
Last Updated: 09/26/2026